Compare Altria Group Inc (MO) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Altria Group Inc trades at $71.54 (market cap $119.25B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.95 (market cap $25.27B). The key difference: Altria Group Inc is far larger — about 4.7× Royalty Pharma plc Class A Ordinary Shares's market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MO | RPRX | |
|---|---|---|
Market Cap | $119.25B | $25.27B |
Volume | 11,178,169 | 3,671,183 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $63.96 |
52-Week Low | $54.72 | $35.44 |
Typical Hold Time | 154 Days | 1 Days |
Enterprise Value | $141.46B | $32.50B |
Dividend Yield | 6.22% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.68, up 3.31% with a bullish technical signal supported by moving averages. The stock shows strong profitability with 72.24% gross margins and 39% net income margin, though revenue has declined from $20.7B in 2022 to $20.1B in 2025. Recent earnings show mixed results with one beat and two misses in the last four quarters. The company maintains a substantial dividend yield with 60 consecutive increases, supported by $9.3B in operating cash flow.
MO presents a high-yield opportunity with analyst consensus favoring Buy ratings (61.5%), but faces significant risks including negative shareholder equity, declining margins, and regulatory pressures. The stock trades below the $69.71 consensus price target, suggesting limited upside potential. Investors must weigh the attractive 6.6% dividend yield against fundamental challenges in the core tobacco business and balance sheet concerns.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
